Table 3. Clinical data: microbiome... | American Society of Hematology

Table 3.

Clinical data: microbiome characteristics and IECT outcomes

Disease	CAR product	Level	Bacteria	Sample size	Country	Outcome or association	Ref
ALL NHL	1928z Axi-cel Tisa-cel CTL019 Brexu-cel	Phylum Class Order Family Genera Species	Bacteroidetes Clostridia Bacteroidia Bacteroidiales Rumminococcaceae Bacteroidaceae Bacteroides Ruminococcus Faecalibacterium Akkermansia Faecalibacterium prausnitzii Ruminococcus bromii	48	United States	D 100 CR	90
		Class Genera Species	Clostridia Ruminococcus Faecalibacterium Faecalibacterium prausnitzii			No toxicity
NHL	Axi-cel Tisa-cel Liso-cel	Genera	Roseburia Bifidobacterium Lactobacillus Eubacterium	116	United States Germany	Non- or “low-risk” antibiotic exposure∗	91
		Species	Bifidobacterium longum Eubacterium eligens Parabacteroides merdae			Alive at 6 mo
		Species	Bacteroides eggerthii Ruminococcus lactaris Eubacterium spp. CAG 180 Akkermansia muciniphila Erysipelatoclostridium ramosum			CR based on deterministic ML model
		Species	Lachnospira pectinoschiza Akkermansia muciniphila			Higher CD3 and CD4 T-cell levels
MM	BCMA CAR-T	Genera	Bifidobacterium Prevotella Sutterella Oscillospira Paraprevotella Collinsella Faecalibacterium Roseburia Ruminococcus	43	China	CR	93
NHL	Not specified	Genera	Faecalibacterium Bifidobacterium Ruminococcus	12
ALL NHL	1928z Axi-cel Tisa-cel CTL019 Brexu-cel	Order Family	Veillonellales Veillonellaceae	48	United States	D 100 non-CR	90
NHL	Axi-cel Tisa-cel Liso-cel	Species	Prevotella Veillonella Enterococcus	116	United States Germany	“High-risk” antibiotic exposure∗	91
		Species	Bacteroides stercoris			Nonresponse based on deterministic ML model
		Species	Bacteroides uniformis Bacteroides ovatus Blautia spp. Faecalibacterium prausnitzii			Lower CD3 and CD8 T-cell levels
ALL	Not specified	Genera	Bifidobacterium Roseburia Collinsella	23	China	Nonresponse	93
MM	BCMA CAR-T	Genera	Bifidobacterium Leuconostoc	43		Severe CRS

Disease	CAR product	Level	Bacteria	Sample size	Country	Outcome or association	Ref
ALL NHL	1928z Axi-cel Tisa-cel CTL019 Brexu-cel	Phylum Class Order Family Genera Species	Bacteroidetes Clostridia Bacteroidia Bacteroidiales Rumminococcaceae Bacteroidaceae Bacteroides Ruminococcus Faecalibacterium Akkermansia Faecalibacterium prausnitzii Ruminococcus bromii	48	United States	D 100 CR	90
		Class Genera Species	Clostridia Ruminococcus Faecalibacterium Faecalibacterium prausnitzii			No toxicity
NHL	Axi-cel Tisa-cel Liso-cel	Genera	Roseburia Bifidobacterium Lactobacillus Eubacterium	116	United States Germany	Non- or “low-risk” antibiotic exposure∗	91
		Species	Bifidobacterium longum Eubacterium eligens Parabacteroides merdae			Alive at 6 mo
		Species	Bacteroides eggerthii Ruminococcus lactaris Eubacterium spp. CAG 180 Akkermansia muciniphila Erysipelatoclostridium ramosum			CR based on deterministic ML model
		Species	Lachnospira pectinoschiza Akkermansia muciniphila			Higher CD3 and CD4 T-cell levels
MM	BCMA CAR-T	Genera	Bifidobacterium Prevotella Sutterella Oscillospira Paraprevotella Collinsella Faecalibacterium Roseburia Ruminococcus	43	China	CR	93
NHL	Not specified	Genera	Faecalibacterium Bifidobacterium Ruminococcus	12
ALL NHL	1928z Axi-cel Tisa-cel CTL019 Brexu-cel	Order Family	Veillonellales Veillonellaceae	48	United States	D 100 non-CR	90
NHL	Axi-cel Tisa-cel Liso-cel	Species	Prevotella Veillonella Enterococcus	116	United States Germany	“High-risk” antibiotic exposure∗	91
		Species	Bacteroides stercoris			Nonresponse based on deterministic ML model
		Species	Bacteroides uniformis Bacteroides ovatus Blautia spp. Faecalibacterium prausnitzii			Lower CD3 and CD8 T-cell levels
ALL	Not specified	Genera	Bifidobacterium Roseburia Collinsella	23	China	Nonresponse	93
MM	BCMA CAR-T	Genera	Bifidobacterium Leuconostoc	43		Severe CRS

ALL, acute lymphoblastic leukemia; axi-cel; axicabtagene ciloleucel; brexu-cel, brexucabtagene autoleucel; liso-cel, lisocabtagene maraleucel; MM, multiple myeloma; tisa-cel, tisagenlecleucel.

∗

“High-risk” antibiotics defined by study as meropenem, cefepime, ceftazidime, and piperacillin-tazobactam. “Low-risk” antibiotic exposure defined by study as exposure to any antibiotic not in the “high-risk” group.⁹¹

View Large

This Feature Is Available To Subscribers Only